Monument Health Rapid City Hospital
- Type
- Teaching hospital
- Where
- Rapid City, SD
- Medicare CCN
- 430077
- Received
- $1,126,367 in 247 records, 2022 ($80,077 general, $1,046,289 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: MONUMENT HEALTH RAPID CITY HOSPITAL Fuzzy (name and state)
- Federal award recipient: MONUMENT HEALTH RAPID CITY HOSPITAL, INC. Fuzzy (name and state)
- Nonprofit: MONUMENT HEALTH RAPID CITY HOSPITAL INC Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 51 | $80,077 |
| 2022 | Research payment | 196 | $1,046,289 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 196 | $1,046,289 |
| Long term medical supply or device loan | 10 | $31,329 |
| Debt forgiveness | 1 | $21,375 |
| Space rental or facility fees (teaching hospital only) | 34 | $20,301 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 3 | $5,780 |
| Grant | 1 | $1,000 |
| Food and Beverage | 2 | $289 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Stryker Corporation | $10,942 | Long term medical supply or device loan | In-kind items and services | INTOUCH Device, PATIENT CARE - PC | 2022 | |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $6,195 | Research payment | In-kind items and services | A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MED | 2022 | |
| 2022-12-31 | AstraZeneca UK Limited | $5,062 | Research payment | In-kind items and services | A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MED | 2022 | |
| 2022-12-31 | Stryker Corporation | $4,420 | Long term medical supply or device loan | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2022 | |
| 2022-12-31 | Stryker Corporation | $2,813 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2022 | |
| 2022-12-31 | AngioDynamics, Inc. | $2,706 | Long term medical supply or device loan | In-kind items and services | VenaCure 1470 Pro Device, ET | 2022 | |
| 2022-12-31 | Stryker Corporation | $2,640 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2022 | |
| 2022-12-31 | Stryker Corporation | $2,329 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2022 | |
| 2022-12-31 | Stryker Corporation | $1,981 | Long term medical supply or device loan | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2022 | |
| 2022-12-31 | Stryker Corporation | $1,522 | Long term medical supply or device loan | In-kind items and services | ISOLIBRIUM Device, PATIENT CARE - PC | 2022 | |
| 2022-12-31 | Stryker Corporation | $1,245 | Long term medical supply or device loan | In-kind items and services | ISOTOUR Device, PATIENT CARE - PC | 2022 | |
| 2022-12-31 | Stryker Corporation | $727 | Long term medical supply or device loan | In-kind items and services | ISOTOUR Device, PATIENT CARE - PC | 2022 | |
| 2022-12-31 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-12-29 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-12-08 | Eli Lilly and Company | $1,199 | Research payment | In-kind items and services | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PL | 2022 | |
| 2022-12-05 | American Regent | $750 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2022 |
| 2022-11-30 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-11-28 | Zimmer Biomet Holdings, Inc. | $5,000 | Research payment | Cash or cash equivalent | Persona Device, Knees | Persona Ti-Nidium Personalized Total Knee System | 2022 |
| 2022-11-23 | Novo Nordisk AS | $2,328 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | NN9924-4437 | 2022 |
| 2022-11-21 | Boston Scientific Corporation | $1,124 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2022 |
| 2022-11-17 | CSL Behring | $618 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-11-17 | CSL Behring | $45 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-11-17 | CSL Behring | $22 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-11-17 | CSL Behring | $4 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-11-16 | Medtronic, Inc. | $6,411 | Research payment | Cash or cash equivalent | COREVALVE EVOLUT R Device, Transcatheter Valve Systems | EXPAND II | 2022 |
| 2022-11-14 | Novo Nordisk AS | $7,114 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | NN9536-4451 | 2022 |
| 2022-11-14 | Novo Nordisk AS | $250 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | NN9536-4451 | 2022 |
| 2022-11-14 | Novo Nordisk AS | $150 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | NN9536-4451 | 2022 |
| 2022-11-09 | American Regent | $7,076 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2022 |
| 2022-11-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-11-07 | Boston Scientific Corporation | $202 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-11-07 | Boston Scientific Corporation | $65 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-11-04 | Esperion Therapeutics, Inc. | $825 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-11-03 | Amgen Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Repatha Biological, Cardiology | 2022 | |
| 2022-11-03 | Lilly USA, LLC | $750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-11-02 | JAZZ PHARMACEUTICALS INC. | $208 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH | 2022 |
| 2022-11-02 | JAZZ PHARMACEUTICALS INC. | $93 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH | 2022 |
| 2022-10-20 | Merck Sharp & Dohme LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VERQUVO Drug, CARDIOVASCULAR | 2022 | |
| 2022-10-17 | American Regent | $12,128 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2022 |
| 2022-10-07 | Esperion Therapeutics, Inc. | $120 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-10-04 | E.R. Squibb & Sons, L.L.C. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2022 | |
| 2022-10-04 | E.R. Squibb & Sons, L.L.C. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | 2022 | |
| 2022-10-03 | Esperion Therapeutics, Inc. | $1,200 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-10-01 | KCI USA, Inc. | $21,375 | Debt forgiveness | Cash or cash equivalent | 2022 | ||
| 2022-09-30 | PFIZER INC. | $1,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2022 | |
| 2022-09-20 | Boston Scientific Corporation | $1,523 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2022 |
| 2022-09-19 | Alnylam Pharmaceuticals Inc. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2022 | |
| 2022-09-16 | DiaSorin Inc. | $4,030 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2022 | ||
| 2022-09-12 | Esperion Therapeutics, Inc. | $120 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-09-07 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BRILINTA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-09-06 | Boston Scientific Corporation | $455 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-09-02 | Genentech, Inc. | $5,000 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | TIRAGOLUMAB TECENTRIQ VS DURVALUMAB IN UNRESECTABLE STAGE III NSCLC | 2022 |
| 2022-08-26 | CSL Behring | $30 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-08-24 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-08-20 | Linde Gas & Equipment Inc. | $733 | Space rental or facility fees (teaching hospital only) | In-kind items and services | MM NO800NI-AQ Device, Respiratory | 2022 | |
| 2022-08-20 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-08-18 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-08-10 | Hikma Pharmaceuticals USA | $209 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-08-09 | Boston Scientific Corporation | $1,000 | Grant | Cash or cash equivalent | GENERAL - THERAPIES Device, THERAPIES | 2022 | |
| 2022-08-04 | Novartis Pharmaceuticals Corporation | $27,520 | Research payment | Cash or cash equivalent | LEQVIO Drug, CARDIOVASCULAR | AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISI | 2022 |
| 2022-08-03 | American Regent | $28,121 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2022 |
| 2022-08-02 | AstraZeneca Pharmaceuticals LP | $1,000 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | Dapagliflozin in Acute Decompensated Heart Failure | 2022 |
| 2022-08-02 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-08-01 | AstraZeneca UK Limited | $14,663 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Multi Centre Study to Evaluate the Efficacy, Safety and Tolera | 2022 |
| 2022-08-01 | Boston Scientific Corporation | $594 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-07-21 | Novartis Pharmaceuticals Corporation | $44,272 | Research payment | Cash or cash equivalent | LEQVIO Drug, CARDIOVASCULAR | A RANDOMIZED, CONTROLLED, MULTICENTER, OPEN-LABEL TRIAL COMPARING A POST-DISCHARGE CARE PATHWAY INVOLVING AGGRESSIVE LDL | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-19 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-07-18 | Boston Scientific Corporation | $1,565 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2022 |
| 2022-07-16 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-07-05 | Boston Scientific Corporation | $594 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-07-01 | Esperion Therapeutics, Inc. | $3,000 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-07-01 | Contego Medical, Inc | $500 | Research payment | Cash or cash equivalent | Neuroguard IEP Device, Cardiovascular | Performance II | 2022 |
| 2022-07-01 | Esperion Therapeutics, Inc. | $480 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-29 | CSL Behring | $164 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-06-29 | CSL Behring | $2 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-06-21 | Boston Scientific Corporation | $7,669 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LUX DX PERFORM | 2022 |
| 2022-06-20 | Gilead Sciences, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2022 | ||
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $1,221 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $150 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $150 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $150 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $150 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-17 | Esperion Therapeutics, Inc. | $150 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-06-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,038 | Research payment | Cash or cash equivalent | Phase II dose finding PoCC in DKD | 2022 | |
| 2022-06-07 | Boston Scientific Corporation | $4,800 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ELEGANCE | 2022 |
| 2022-05-26 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-05-25 | Novo Nordisk AS | $159 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | NN9924-4437 | 2022 |
| 2022-05-24 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-05-23 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-23 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-05-21 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-05-20 | CSL Behring | $837 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-05-16 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | APPRAISE ATP | 2022 |
| 2022-05-16 | Boston Scientific Corporation | $501 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LUX DX PERFORM | 2022 |
| 2022-05-11 | American Regent | $1,209 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2022 |
| 2022-05-10 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-05-02 | Merge Healthcare Incorporated | $80 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2022 | |
| 2022-04-29 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-04-29 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-04-29 | Novo Nordisk AS | $474 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | NN9536-4451 | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-04-21 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-04-20 | American Regent | $13,908 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2022 |
| 2022-04-19 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-04-18 | Boston Scientific Corporation | $250 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LUX DX PERFORM | 2022 |
| 2022-04-13 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-03-31 | JAZZ PHARMACEUTICALS INC. | $1,788 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH | 2022 |
| 2022-03-29 | JAZZ PHARMACEUTICALS INC. | $150 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH | 2022 |
| 2022-03-26 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-03-24 | Penumbra, Inc. | $750 | Research payment | Cash or cash equivalent | Indigo System Device, Peripheral Intervention | CHEETAH | 2022 |
| 2022-03-22 | Amgen Inc. | $1,701 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | 20130295-FOURIER OLE (Ph 4) | 2022 |
| 2022-03-22 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-03-21 | Eli Lilly and Company | $7,410 | Research payment | Cash or cash equivalent | A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | 2022 | |
| 2022-03-21 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-21 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-18 | CSL Behring | $270 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2022 | |
| 2022-03-16 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-03-14 | AstraZeneca UK Limited | $19,732 | Research payment | Cash or cash equivalent | A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MED | 2022 | |
| 2022-03-14 | Abbott Laboratories | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FREESTYLE LIBRE 2 Device, Diabetes Care | 2022 | |
| 2022-03-11 | Linde Gas & Equipment Inc. | $330 | Space rental or facility fees (teaching hospital only) | In-kind items and services | REQNOXBOX-I Device, Respiratory | 2022 | |
| 2022-03-10 | JAZZ PHARMACEUTICALS INC. | $4,000 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH | 2022 |
| 2022-03-09 | Esperion Therapeutics, Inc. | $240 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-07 | American Regent | $1,819 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Iron Deficiency Anemia | Heart_FID | 2022 |
| 2022-03-04 | JAZZ PHARMACEUTICALS INC. | $280 | Research payment | Cash or cash equivalent | ZEPZELCA Drug, HEMATOLOGY/ONCOLOGY | EMERGE 402: PHASE IV OBSERVATIONAL STUDY TO COLLECT SAFETY AND OUTCOME DATA IN REAL-WORLD SETTING IN ADULT PATIENTS WITH | 2022 |
| 2022-03-03 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | 2022 | |
| 2022-03-02 | Novartis Pharmaceuticals Corporation | $76,883 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | $572 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
| 2022-03-01 | Esperion Therapeutics, Inc. | $354 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2022 |
The latest 200 records of 247.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rapid City, SD, county Pennington County, SD, state South Dakota; placed by its city name.
| Measure | Place (city or town) Rapid City, SD | County Pennington County, SD | State South Dakota |
|---|---|---|---|
| Population B01003 | 77,946 | 113,512 | 907,428 |
| Population, 2020 census P1 | 74,703 | 109,222 | 886,667 |
| Median age B01002 | 39.1 | 40.1 | 38.0 |
| Under 18 B01001 | 22.0% | 22.0% | 24.2% |
| 65 and over B01001 | 20.7% | 20.1% | 18.0% |
| Households B11001 | 32,368 | 46,370 | 365,544 |
| Foreign born B05002 | 2.6% | 2.5% | 4.0% |
| Median household income B19013 | $70,870 | $74,517 | $75,081 |
| Median family income B19113 | $91,802 | $92,479 | $96,562 |
| Per capita income B19301 | $42,204 | $42,302 | $40,550 |
| Poverty rate B17001 | 12.5% | 11.2% | 11.9% |
| Unemployment rate B23025 | 2.6% | 3.2% | 2.9% |
| Civilian labor force B23025 | 39,452 | 57,369 | 475,223 |
| Mean commute (minutes) B08013 | 17.5 | 19.4 | 17.8 |
| Bachelor's degree or higher B15003 | 37.0% | 34.6% | 31.9% |
| Housing units B25001 | 35,577 | 51,681 | 408,584 |
| Owner-occupied B25003 | 62.9% | 69.3% | 68.6% |
| Renters B25003 | 37.1% | 30.7% | 31.4% |
| Median home value B25077 | $299,400 | $302,200 | $257,400 |
| Median gross rent B25064 | $1,109 | $1,120 | $946 |
| White, not Hispanic B03002 | 76.3% | 77.8% | 79.8% |
| Black B03002 | 1.2% | 1.1% | 2.1% |
| Hispanic or Latino B03002 | 6.1% | 5.7% | 4.8% |
| Asian B03002 | 1.3% | 1.2% | 1.4% |
| American Indian and Alaska Native B03002 | 7.1% | 6.0% | 7.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rapid City, SD.
Comments